Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-613 with Bendamustine and Rituximab in Relapsed/Refractory B-Cell NHL
NCT02168907Phase 1Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Dec 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of devimistat in B-cell non-Hodgkin lymphoma, sponsored by Wake Forest University Health Sciences. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started Dec 2014; status: terminated.
02
Drugs
devimistat
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02168907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02168907.